Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropsychiatric and Pain Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GIRK2/KCNJ6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GIRK2/KCNJ6 Recombinant Protein Sequence Verified. High Purity (>95%). HEK293 Expressed for native post-translational modifications. |
View GIRK2 Products |
| Gene Delivery | GIRK2/KCNJ6 Lentivirus Premade Particles Full-length ORF designed for stable cell line construction to preserve native membrane conformation. |
View GIRK2 Products |
| Benchmark Ab | Anti-GIRK2/KCNJ6 Benchmark Antibody Recombinant positive control for surface expression validation. |
View GIRK2 Products |
| Validator | GIRK2/KCNJ6 siRNA Set Target-specific knockdown verification in functional assays. |
View GIRK2 Products |
| Related Target A | GIRK1/KCNJ3 Forms functional heterotetramers with GIRK2 in the central nervous system; critical for physiological channel activity. |
View GIRK1 Products |
| Related Target B | GABAB Receptor GPCR partner that directly gates GIRK2 channels via G-protein beta-gamma subunits. |
View GABAB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | Lentivirus-mediated stable cell line expression preserves native 4-transmembrane topology and tetrameric assembly. |
| Subfamily Off-target Screening (GIRK4/KCNJ5 Counter-screening) | Homolog panel reagents and cell-based platforms strictly verified by sequence and functional expression. |
| Lack of Controls | Clinical-grade benchmark antibodies included as reference standards. |
| False Positives in Small Molecule Screens | Sequence-verified siRNA included for target-specific knockdown validation. |
Live GIRK2/KCNJ6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GIRK2/KCNJ6 therapeutics is intensifying, with major players shifting focus from non-selective ion channel modulators to highly selective allosteric modulators. As first-generation pain and neuropsychiatric therapies reach the clinic, the next wave of R&D is targeting the precise heterotetrameric interfaces of GIRK1/2 channels to avoid systemic adverse effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | Academic Consortia, Neuro-focused Biotech | Epilepsy, Severe Pain, Drug Addiction | Electrophysiology & Flux Assays (Need Lentivirus for Stable Cell Lines) |
| Gene Therapy | Preclinical Gene Therapy Developers | Neuropathic Pain, Down Syndrome | Expression Validation (Need High-Purity Recombinant Proteins) |
| Monoclonal Antibodies | Targeted Immunotherapy Biotechs | Neurological Autoimmune Conditions | Epitope Mapping (Need Sequence-Verified Antigen Panels) |